Roquette Opens New Asia Pacific Headquarters and Innovation Center in Singapore

News
Article

The company has opened new facilities and an innovation center in Singapore, China that will focus on the development of plant-based products.

On Oct. 26, 2017, Roquette announced the opening of previously announced new facilities and an innovation center in Singapore, China. According to the company, the facilities will be focused on plant-based pharma, food, and nutrition products specific to regional health trends.

“As a global business leader, we know that we need to adapt our solutions to the specific needs of the different markets. By expanding our international research capability, we can ensure our products contribute to improving health and well-being of millions of consumers around the world,” said Jean-Marc Gilson, CEO of Roquette, in a company press release. “Our facilities in Singapore will allow us to explore new ways to address specific health and nutrition needs of Asian customers and consumers through plant-based ingredients such as sugar alternatives, vegetal proteins or pharmaceutical excipients, among many others.”

Features of the new facilities include a research laboratory, customer technical services, and a new regional headquarters, and will enable the company to partner with customers, universities, and research institutions for solutions, such as Singapore’s Agency for Science, Technology and Research (A*STAR) or the National University of Singapore.

This latest announcement follows a series of recent global investments by the company, including the September 2017 acquisition of Itacel, previously an excipient division of Blanver, a Brazilian multinational company.

Source: Roquette

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content